D. E. Shaw & Co., Inc. Ionis Pharmaceuticals Inc Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 145,091 shares of IONS stock, worth $4.93 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

145,091

Holding current value

$4.93 Million

% of portfolio

0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$40.06 - $51.86 $1.83 Million - $2.37 Million	-45,690 Reduced 23.95%	145,091 $5.81 Million
Q2 2024 Aug 14, 2024	BUY	$36.45 - $47.7 $1.1 Million - $1.45 Million	30,299 Added 18.88%	190,781 $9.09 Million
Q1 2024 May 15, 2024	BUY	$42.03 - $53.55 $1.74 Million - $2.21 Million	41,324 Added 34.68%	160,482 $6.96 Million
Q4 2023 Feb 14, 2024	SELL	$43.39 - $51.63 $10.5 Million - $12.5 Million	-242,887 Reduced 67.09%	119,158 $6.03 Million
Q3 2023 Nov 14, 2023	BUY	$38.5 - $47.13 $6.38 Million - $7.82 Million	165,832 Added 84.52%	362,045 $16.4 Million
Q2 2023 Aug 14, 2023	BUY	$34.73 - $43.33 $3.81 Million - $4.75 Million	109,562 Added 126.44%	196,213 $8.05 Million
Q1 2023 May 15, 2023	SELL	$33.58 - $41.2 $7.14 Million - $8.76 Million	-212,580 Reduced 71.04%	86,651 $3.1 Million
Q4 2022 Feb 14, 2023	BUY	$37.12 - $46.52 $3.33 Million - $4.18 Million	89,786 Added 42.87%	299,231 $11.3 Million
Q3 2022 Nov 14, 2022	BUY	$36.54 - $48.66 $3.03 Million - $4.03 Million	82,824 Added 65.41%	209,445 $9.26 Million
Q2 2022 Aug 15, 2022	BUY	$31.71 - $43.0 $4.02 Million - $5.44 Million	126,621 New	126,621 $4.69 Million
Q1 2022 May 16, 2022	SELL	$29.88 - $37.04 $4.8 Million - $5.95 Million	-160,659 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$25.61 - $35.1 $884,902 - $1.21 Million	34,553 Added 27.4%	160,659 $4.89 Million
Q3 2021 Nov 15, 2021	BUY	$33.54 - $40.55 $1.73 Million - $2.09 Million	51,440 Added 68.89%	126,106 $4.23 Million
Q2 2021 Aug 16, 2021	BUY	$34.54 - $47.25 $2.3 Million - $3.14 Million	66,560 Added 821.12%	74,666 $2.98 Million
Q1 2021 May 17, 2021	SELL	$42.51 - $63.78 $225,770 - $338,735	-5,311 Reduced 39.58%	8,106 $364,000
Q4 2020 Feb 16, 2021	SELL	$45.3 - $60.27 $9.5 Million - $12.6 Million	-209,732 Reduced 93.99%	13,417 $759,000
Q3 2020 Nov 16, 2020	BUY	$47.45 - $62.95 $5.23 Million - $6.94 Million	110,277 Added 97.7%	223,149 $10.6 Million
Q2 2020 Aug 14, 2020	BUY	$46.85 - $61.05 $4.12 Million - $5.36 Million	87,876 Added 351.56%	112,872 $6.66 Million
Q1 2020 May 15, 2020	SELL	$41.6 - $63.4 $21.8 Million - $33.2 Million	-524,362 Reduced 95.45%	24,996 $1.18 Million
Q4 2019 Feb 14, 2020	SELL	$53.85 - $65.27 $15.1 Million - $18.3 Million	-280,132 Reduced 33.77%	549,358 $33.2 Million
Q3 2019 Nov 14, 2019	BUY	$59.06 - $72.15 $5.7 Million - $6.96 Million	96,531 Added 13.17%	829,490 $49.7 Million
Q2 2019 Aug 14, 2019	BUY	$62.09 - $86.14 $10.9 Million - $15.1 Million	175,768 Added 31.55%	732,959 $47.1 Million
Q1 2019 May 15, 2019	BUY	$52.92 - $81.17 $7.75 Million - $11.9 Million	146,492 Added 35.67%	557,191 $45.2 Million
Q4 2018 Feb 14, 2019	BUY	$43.37 - $59.54 $12.8 Million - $17.5 Million	294,184 Added 252.49%	410,699 $22.2 Million
Q3 2018 Nov 14, 2018	BUY	$42.88 - $53.7 $4.47 Million - $5.6 Million	104,215 Added 847.28%	116,515 $6.01 Million
Q2 2018 Aug 14, 2018	SELL	$40.53 - $50.7 $505,084 - $631,823	-12,462 Reduced 50.33%	12,300 $513,000
Q1 2018 May 15, 2018	SELL	$44.08 - $55.05 $2.41 Million - $3.01 Million	-54,723 Reduced 68.85%	24,762 $1.09 Million
Q4 2017 Feb 14, 2018	BUY	$50.3 - $64.39 $649,725 - $831,725	12,917 Added 19.4%	79,485 $4 Million
Q3 2017 Nov 14, 2017	BUY	$45.56 - $59.57 $3.03 Million - $3.97 Million	66,568	66,568 $3.38 Million

Others Institutions Holding IONS

# of Institutions

402

Shares Held

136M

Call Options Held

862K

Put Options Held

582K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $4.83B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account